Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia (DIREMOS)
Continuous, Real-time, Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia: Discharge Remote Monitoring System (DIREMOS)
Sponsor: DexCom, Inc.
Listed as NCT05746286, this NA trial focuses on Dysglycemia and remains completed. Sponsored by DexCom, Inc., it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
3 versions recorded-
Dec 2025 — Present [monthly]
Completed NA
Status: Withheld → Completed · Phase: None → NA
-
Sep 2024 — Dec 2025 [monthly]
Withheld
-
Mar 2023 — Sep 2024 [monthly]
Withheld
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- DexCom, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .